REFERENCES
- Aiello L P, George D J, Cahill M T, Wong J S, Cavallerano J, Hannah A L, et al. Rapid and durable recovery of visual function in a patient with von Hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002; 109(9)1745–51, [INFOTRIEVE], [CSA]
- Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 2004; 49(3)203–20, [INFOTRIEVE], [CSA]
- Bergers G, Benjamin L E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6)401–10, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 2003; 27(3)229–38, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Boyd S R, Tan D, Bunce C, Gittos A, Neale M H, Hungerford J L, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002; 86(4)448–52, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Boyd S R, Tan D S, de Souza L, Neale M H, Myatt N E, Alexander R A, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002; 86(4)440–7, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004; 14(2)139–45, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Cao Y, Xue L. Angiostatin. Semin Thromb Hemost 2004; 30(1)83–93, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6(4)389–95, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255(5)538–61, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801)249–57, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Chu E. Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer. Clin Colorectal Cancer 2004; 4(1)16, [INFOTRIEVE], [CSA]
- Dvorak H F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26)1650–9, [INFOTRIEVE], [CSA]
- Ferrara N. 2000. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11(6)617–24, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Fine H A, Figg W D, Jaeckle K, Wen P Y, Kyritsis A P, Loeffler J S, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18(4)708–15, [INFOTRIEVE], [CSA]
- Fine H A, Wen P Y, Maher E A, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21(12)2299–304, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82(1)4–6, [INFOTRIEVE], [CSA]
- Girmens J F, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003; 136(1)194–6, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3)353–64, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Hendrix M J, Seftor E A, Hess A R, Seftor R E. Vasculogenic mimicry and tumour–cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3(6)411–21, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Hynes R O. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8(9)918–21, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Ijland S A, Jager M J, Heijdra B M, Westphal J R, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999; 9(5)445–50, [INFOTRIEVE], [CSA]
- Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001; 52(1–2)61–6, [INFOTRIEVE], [CSA]
- Kure T, Chang J H, Kato T, Hernandez-Quintela E, Ye H, Lu P C, et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci 2003; 44(1)137–44, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Lane A M, Egan K M, Yang J, Saornil M A, Alroy J, Albert D, et al. An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res 1997; 7(3)237–42, [INFOTRIEVE], [CSA]
- Lin H C, Chang J H, Jain S, Gabison E E, Kure T, Kato T, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42(11)2517–24, [INFOTRIEVE], [CSA]
- Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5(4)237–56, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Madhusudan S, Deplanque G, Braybrooke J P, Cattell E, Taylor M, Price P, et al. Antiangiogenic therapy for von Hippel-Lindau disease. Jama 2004; 291(8)943–4, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Marback E F, Arias V E, Paranhos A, Jr, Soares F A, Murphree A L, Erwenne C M. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 2003; 87(10)1224–28, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Marme D. The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003; 129(11)607–20, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Maxwell P H, Wiesener M S, Chang G W, Clifford S C, Vaux E C, Cockman M E, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399(6733)271–5, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- McCarty M F, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003; 9(2)53–8, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain R K, McDonald D M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160(3)985–1000, [INFOTRIEVE], [CSA]
- Offodile R, Walton T, Lee M, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 1999; 85(1)51–3, [INFOTRIEVE], [CSA]
- Ravi R, Mookerjee B, Bhujwalla Z M, Sutter C H, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14(1)34–44, [INFOTRIEVE], [CSA]
- Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schuler A, et al. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 2004; 164(2)391–4, [INFOTRIEVE], [CSA]
- Sheidow T G, Hooper P L, Crukley C, Young J, Heathcote J G. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 2000; 84(7)750–6, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004; 27(5)599–605, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Shokravi M T, Marcus D M, Alroy J, Egan K, Saornil M A, Albert D M. Vitamin D. inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995; 36(1)83–7, [INFOTRIEVE], [CSA]
- Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398)843–5, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Singh A D, Shields C L, Shields J A. von Hippel-Lindau disease. Surv Ophthalmol 2001; 46(2)117–42, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Soni S, Lee D S, DiVito J, Jr, Bui A H, DeRaffele G, Radel E, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol 2002; 24(6)488–91, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Stitt A W, Gardiner T A. Anti-angiogenic therapy for uveal melanoma—more haste, less speed. Br J Ophthalmol 2002; 86(4)368–9, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Suri C, Jones P F, Patan S, Bartunkova S, Maisonpierre P C, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87(7)1171–80, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Sweeney C J, Miller K D, Sledge G W, Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution?. Trends Mol Med 2003; 9(1)24–9, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Embo J 2000; 19(16)4298–309, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Tapper D, Langer R, Bellows A R, Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery 1979; 86(1)36–40, [INFOTRIEVE], [CSA]
- Visconti R P, Richardson C D, Sato T N. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002; 99(12)8219–24, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Wang G L, Jiang B H, Rue E A, Semenza G L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92(12)5510–4, [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis L M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000; 60(13)3655–61, [INFOTRIEVE], [CSA]
- Zondor S D, Medina P J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38(7–8)1258–64, [INFOTRIEVE], [CSA]